NCT05084339

Brief Summary

The aim of the GLORIA study is to determine whether an altered glucose metabolism (with more hypoglycaemia and glycaemic variability) and altered metabolomics during pregnancy after bariatric surgery contribute to the increased risk for adverse pregnancy outcomes such as small-for-gestational age infants. In addition, the investigators also aim to evaluate whether continuous glucose monitoring (CGM) can be used to diagnose gestational diabetes (GDM).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
190

participants targeted

Target at P50-P75 for all trials

Timeline
7mo left

Started Jan 2023

Longer than P75 for all trials

Geographic Reach
1 country

8 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress85%
Jan 2023Dec 2026

First Submitted

Initial submission to the registry

September 20, 2021

Completed
29 days until next milestone

First Posted

Study publicly available on registry

October 19, 2021

Completed
1.3 years until next milestone

Study Start

First participant enrolled

January 25, 2023

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

May 5, 2026

Status Verified

April 1, 2026

Enrollment Period

3.6 years

First QC Date

September 20, 2021

Last Update Submit

April 28, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • mean glycaemia

    mean glycaemia measured by CGM

    between 6-12 weeks of pregnancy, 18-22 weeks of pregnancy, 24-28 weeks of pregnancy and 30-34 weeks of pregnancy

  • Standard deviation of glycaemia

    SD measured by CGM

    between 6-12 weeks of pregnancy, 18-22 weeks of pregnancy, 24-28 weeks of pregnancy and 30-34 weeks of pregnancy

Secondary Outcomes (32)

  • time <54mg/dl

    between 6-12 weeks of pregnancy, 18-22 weeks of pregnancy, 24-28 weeks of pregnancy and 30-34 weeks of pregnancy

  • glycaemic variability measured by coefficient of variation (CV)

    between 6-12 weeks of pregnancy, 18-22 weeks of pregnancy, 24-28 weeks of pregnancy and 30-34 weeks of pregnancy

  • glycaemic variability measured by mean amplitude of glucose excursions (MAGE)

    between 6-12 weeks of pregnancy, 18-22 weeks of pregnancy, 24-28 weeks of pregnancy and 30-34 weeks of pregnancy

  • time <70mg/dl

    between 6-12 weeks of pregnancy, 18-22 weeks of pregnancy, 24-28 weeks of pregnancy and 30-34 weeks of pregnancy

  • time <63mg/dl

    between 6-12 weeks of pregnancy, 18-22 weeks of pregnancy, 24-28 weeks of pregnancy and 30-34 weeks of pregnancy

  • +27 more secondary outcomes

Study Arms (2)

pregnant group with bariatric surgery

pregnant women with a history of gastric bypass or sleeve gastrectomy

Diagnostic Test: CGM

matched pregnant group without history of bariatric surgery

age-and BMI matched pregnant women without history of bariatric surgery

Diagnostic Test: CGM

Interventions

CGMDIAGNOSTIC_TEST

blinded CGM used at 4 different time points in pregnancy

matched pregnant group without history of bariatric surgerypregnant group with bariatric surgery

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

95 pregnant women with a history of bariatric surgery (RYBG or SG) and 95 age-and BMO matched pregnant women without history of bariatric surgery

You may qualify if:

  • Age 18-45 years and with a singleton pregnancy with ultrasound-confirmed gestational age up to 11 weeks and 6 days
  • for the group with bariatric surgery: history of gastric bypass (RYBG) or sleeve gastrectomy (SG)
  • Participants need to speak and understand Flemish, French or English and have e-mail access.

You may not qualify if:

  • multiple pregnancy
  • pregnancy ≥12 weeks
  • other types of bariatric surgery than RYBG or SG
  • known pregestational diabetes
  • a physical or psychological disease likely to interfere with the conduct of the study
  • medications known to interfere with glucose metabolism.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

OLV-Aalst-Asse

Aalst, Belgium

RECRUITING

UZA

Antwerp, Belgium

RECRUITING

ZNA Antwerpen

Antwerp, Belgium

RECRUITING

Imelda Bonheiden

Bonheiden, Belgium

RECRUITING

AZ St-Jan Brugge

Bruges, Belgium

RECRUITING

UZ Gent

Ghent, Belgium

RECRUITING

AZ Groeninge Kortrijk

Kortrijk, Belgium

RECRUITING

UZ Leuven

Leuven, Belgium

RECRUITING

Related Publications (1)

  • Deleus E, Bochanen N, Ceulemans D, Debunne H, Denys B, Devlieger R, Geerts I, Laenen A, Jochems L, Lannoey E, Lannoo M, Loccufier A, Maes T, Marlier J, Morrens A, Myngheer N, Tierens L, Vandenberghe G, Van den Bruel A, Van den Haute L, Van der Schueren B, Van Pottelbergh I, Benhalima K. Glucose Homeostasis, Metabolomics, and Pregnancy Outcomes After Bariatric Surgery (GLORIA): Protocol for a Multicentre Prospective Cohort Study. J Clin Med. 2025 Jul 7;14(13):4782. doi: 10.3390/jcm14134782.

Study Officials

  • Katrien Benhalima, MD PhD

    UZ Leuven

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Katrien Benhalima, MD PhD

CONTACT

Ellen Deleus, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 20, 2021

First Posted

October 19, 2021

Study Start

January 25, 2023

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

May 5, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations